Sol-Gel Technologies Total Depreciation and Amortization - Cash Flow 2016-2024 | SLGL
Sol-Gel Technologies total depreciation and amortization - cash flow from 2016 to 2024. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
Sol-Gel Technologies Annual Total Depreciation and Amortization - Cash Flow
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$0 |
| 2022 |
$1 |
| 2021 |
$1 |
| 2020 |
$1 |
| 2019 |
$1 |
| 2018 |
$1 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.021B |
$0.012B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
